Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
4.32
USD
|
-1.82%
|
|
-10.19%
|
-6.29%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
16.73
|
13.98
|
5.364
|
6.372
|
5.861
|
-
|
-
|
Enterprise Value (EV)
1 |
16.73
|
13.98
|
5.364
|
6.372
|
5.861
|
5.861
|
5.861
|
P/E ratio
|
-0.21
x
|
0.39
x
|
-0.41
x
|
-1.23
x
|
-0.92
x
|
-1.15
x
|
1.79
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
159
x
|
60.5
x
|
708
x
|
-
|
10.4
x
|
0.25
x
|
EV / Revenue
|
-
|
159
x
|
60.5
x
|
708
x
|
-
|
10.4
x
|
0.25
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
120
|
633
|
1,408
|
1,382
|
1,357
|
-
|
-
|
Reference price
2 |
139.0
|
22.10
|
3.811
|
4.610
|
4.320
|
4.320
|
4.320
|
Announcement Date
|
3/17/21
|
3/30/22
|
3/31/23
|
3/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.0878
|
0.0886
|
0.009
|
-
|
0.563
|
23.41
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-3.126
|
-10.24
|
-5.62
|
-6.353
|
-6.144
|
9.681
|
Operating Margin
|
-
|
-3,562.34%
|
-11,562.49%
|
-62,445.89%
|
-
|
-1,091.3%
|
41.36%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-10.14
|
-5.287
|
-6.353
|
-6.144
|
9.681
|
Net income
1 |
-36.33
|
19.21
|
-10.14
|
-5.287
|
-6.353
|
-6.144
|
9.681
|
Net margin
|
-
|
21,893.75%
|
-11,449.26%
|
-58,739.67%
|
-
|
-1,091.3%
|
41.36%
|
EPS
2 |
-650.0
|
56.10
|
-9.300
|
-3.760
|
-4.680
|
-3.770
|
2.420
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/17/21
|
3/30/22
|
3/31/23
|
3/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
0.0678
|
0.015
|
-
|
0.055
|
0.0186
|
-
|
-
|
0.006
|
0.003
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-1.473
|
-1.155
|
-1.791
|
-1.02
|
-6.278
|
-1.113
|
-1.192
|
-1.543
|
-1.772
|
-1.565
|
-1.58
|
-1.596
|
-1.612
|
Operating Margin
|
-2,173.77%
|
-7,699.13%
|
-
|
-1,855.31%
|
-33,752.37%
|
-
|
-
|
-25,719.83%
|
-59,061.33%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-1.791
|
-0.9823
|
-6.216
|
-1.052
|
-1.102
|
-1.454
|
-1.679
|
-1.565
|
-1.58
|
-1.596
|
-1.612
|
Net income
1 |
-3.875
|
-1.155
|
-1.791
|
-0.9823
|
-6.216
|
-1.052
|
-1.102
|
-1.454
|
-1.679
|
-1.565
|
-1.58
|
-1.596
|
-1.612
|
Net margin
|
-5,720.25%
|
-7,699.13%
|
-
|
-1,786.07%
|
-33,417.69%
|
-
|
-
|
-24,232.5%
|
-55,952.33%
|
-
|
-
|
-
|
-
|
EPS
2 |
-41.60
|
-1.800
|
-2.000
|
-0.7000
|
-5.300
|
-0.7000
|
-0.7800
|
-1.020
|
-1.210
|
-1.150
|
-1.160
|
-1.180
|
-1.190
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/22
|
5/13/22
|
8/12/22
|
11/10/22
|
3/31/23
|
5/12/23
|
8/11/23
|
11/14/23
|
3/22/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/17/21
|
3/30/22
|
3/31/23
|
3/22/24
|
-
|
-
|
-
|
Last Close Price
4.32
USD Average target price
30
USD Spread / Average Target +594.44% Consensus |
1st Jan change
|
Capi.
|
---|
| -6.29% | 5.86M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|